(9aR)-Hexahydropyrazino[2,1-c][1,4]oxazin-4(3H)-one → HCID 58117059, 화합물
반응식
[Cl:1][C:2]1[N:3]=[C:4]([N:22]2[CH2:27][CH2:26][O:25][CH2:24][CH2:23]2)[C:5]2[S:10][C:9]([CH2:11][N:12]3[CH2:17][CH2:16][NH:15][C:14](=[O:18])[C@@H:13]3C(C)C)=[CH:8][C:6]=2[N:7]=1.[CH2:28]1[C@H:33]2[CH2:34]NCCN2C(=O)C[O:29]1>>[Cl:1][C:2]1[N:3]=[C:4]([N:22]2[CH2:23][CH2:24][O:25][CH2:26][CH2:27]2)[C:5]2[S:10][C:9]([CH2:11][N:12]3[CH2:17][CH2:16][N:15]4[C@@H:33]([CH2:28][O:29][CH2:13][C:14]4=[O:18])[CH2:34]3)=[CH:8][C:6]=2[N:7]=1참가 물질
3
실험 절차
Prepared according to the method used in the preparation of (S)-4-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-3-isopropyl-piperazin-2-one using (R)-hexahydro-pyrazino[2,1-c][1,4]oxazin-4-one in place of (S)-3-isopropyl-piperazin-2-one. The title compound was obtained as a tan solid (79 mg, 69%).
후처리
- customPrepared
출처 및 근거
- ORD 기록
- ord-f8fea36a39534544b954347e85506790
- 출처 데이터셋
- uspto-grants-2012_10
- DOI